ArticleJournal of materials chemistry. B2015
Theranostic CuS Nanoparticles Targeting Folate Receptors for PET Image-Guided Photothermal Therapy.
Article in Journal of materials chemistry. B, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 59 citations in OpenAlex.
- Metal-Based Therapeutic Approaches for Overcoming Cancer Drug Resistance: Mechanisms, Drug Delivery Strategies, and Clinical Perspectives.Oncology research · 2026Review
- Advances in Versatile Copper Sulfide-Based Nanoplatforms: From Synthesis and Properties to Multifaceted Biomedical Applications.International journal of nanomedicine · 2026Review
- Ultra-small NIR-Responsive Nanotheranostic Agent for Targeted Photothermal Ablation Induced Damage-Associated Molecular Patterns (DAMPs) from Post-PTT of Tumor Cells Activate Immunogenic Cell Death.Nanotheranostics · 2023Article
- Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.Frontiers in medicine · 2022Review
- Near-infrared light triggered activation of pro-drug combination cancer therapy and induction of immunogenic cell death.International journal of pharmaceutics · 2021Article
- An In Vivo Study of a Rat Fluid-Percussion-Induced Traumatic Brain Injury Model with [International journal of molecular sciences · 2021Article
- Radiolabeling of Theranostic Nanosystems.Advances in experimental medicine and biology · 2021Article
- Recent Progress on NIR-II Photothermal Therapy.Frontiers in chemistry · 2021Review
- The Coppery Age: Copper (Cu)-Involved Nanotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Thermosensitive Biodegradable Copper Sulfide Nanoparticles for Real-Time Multispectral Optoacoustic Tomography.ACS applied bio materials · 2019Article
- A theranostic agent for cancer therapy and imaging in the second near-infrared window.Nano research · 2019Article
- The combined therapeutic effects ofActa pharmaceutica Sinica. B · 2018Article
- Article
- Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2017Review
- Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.Advanced drug delivery reviews · 2017Review
- Dual wavelength stimulation of polymeric nanoparticles for photothermal therapy.Lasers in surgery and medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Copper sulfide nanoparticles (CuS NPs) have been reported as a single-compartment theranostic nanosystem to visualize and treat tumors simultaneously. However, few studies have investigated the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.